Tech Note 5: SIMI: A Different Approach to Revealing Dangerous Subvisible Impurities
Please fill out the form to download the tech note.
Read MoreGene Therapy: Critical Quality Attributes of Viral Vector and Lipid Nanoparticle Stability
There is a growing appreciation that the biggest hurdle toward realizing the full clinical potential of human gene therapy and…
Read MoreParticle Vue 21 CFR Part 11 Documentation
Download PDF
Read MoreVirtual Seminar – AAV Vector Stability With BMI – Are Your Analytics Giving You The Whole Picture? – April 2020
Subvisible particle (SVP) analysis in parenteral formulations is a key predictor of safety and efficacy, and an essential drug quality…
Read MoreBMI Count And Size Validation With Aura
The Aura™ system, with its ability to count, size, and ID particles, is a powerful tool for biologics and gene…
Read MoreCharacterizing the Stability of Gene Therapy Products at Ultra Low Volume
In this GEN webinar, Dr. Bernardo Cordovez will discuss Aura® GT and how to characterize gene therapies for stability and…
Read MoreHigh Throughput Characterization Of Antibody, AAV And Cell Therapy Aggregates And Particulate Impurities Using The Aura
Presented live at Oxford Global’s Biotherapeutics US conference held in Boston, MA, Dr. Bernardo Cordovez presented how to identify protein…
Read MoreHigh Throughput, Low Volume Product Stability and Purity Analysis for AAV and Lentiviral Gene Therapies
Aura+ is the latest instrument designed specifically to detect, count, and characterize subvisible aggregates and extrinsic materials for product quality…
Read MoreOptimizing AAV Vectors for Gene Therapy Delivery
Adeno-associated viruses (AAV) can be engineered to deliver DNA to target cells. It is used extensively for the development of…
Read MoreHalo U: Intro To Aura And BMI 101
This is our first virtual course to demonstrate the easy usability of performing high throughput, low volume subvisible particle analysis…
Read More